Monday, 16 November 2026Follow on 𝕏

FDA calendar

Upcoming FDA decision dates, advisory committee meetings and EU opinions, alongside recent FDA decisions and announcements. Updated automatically every day from the FDA newsroom, openFDA, the Federal Register and company announcements.

Coming up

No upcoming events yet.

Recent FDA decisions and announcements

November 2026

October 2026

  • 30Fri
    FDA approval
    FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
    FDA press release β†—
  • 30Fri
    FDA approval
    FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
    FDA press release β†—
  • 27Tue
    FDA approval
    Xbrane Biopharma Ab Β· Lucamzi (ranibizumab-blrz)
    New biologic licence
    Drugs@FDA β†—
  • 22Thu
    FDA approval
    Sandoz Inc Β· Enzeevu (aflibercept-abzv)
    New biologic licence
    Drugs@FDA β†—
  • 22Thu
    FDA approval
    Formycon AG Β· Ahzantive (aflibercept-mrbb)
    New biologic licence
    Drugs@FDA β†—
  • 22Thu
    FDA approval
    Amgen Inc Β· Pavblu (aflibercept-ayyh)
    New biologic licence
    Drugs@FDA β†—
  • 20Tue
    FDA approval
    Glaxosmithkline LLC Β· Hibsago (bepirovirsen)
    New molecular entity, priority review
    Drugs@FDA β†—
  • 20Tue
    FDA approval
    FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women
    FDA press release β†—
  • 20Tue
    FDA approval
    FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment
    FDA press release β†—
  • 19Mon
    FDA approval
    FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
    FDA press release β†—
  • 19Mon
    FDA approval
    FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
    FDA press release β†—
  • 14Wed
    FDA approval
    FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
    FDA press release β†—
  • 9Fri
    FDA approval
    Aicuris Anti-Infect Β· Hovilpri (pritelivir mesylate)
    New molecular entity, priority review
    Drugs@FDA β†—

September 2026

  • 28Mon
    FDA approval
    FDA Approves First Treatment for MCT8 Deficiency
    FDA press release β†—
  • 28Mon
    FDA approval
    Rare Thyroid Β· Emcitate (tiratricol)
    New molecular entity, priority review
    Drugs@FDA β†—
  • 25Fri
    FDA approval
    Mirum Β· Atebrioz (zilurgisertib fumarate)
    New molecular entity, priority review
    Drugs@FDA β†—
  • 23Wed
    FDA approval
    Elevar Β· Lyrfigtu (lirafugratinib hydrochloride)
    New molecular entity, priority review
    Drugs@FDA β†—
  • 17Thu
    FDA approval
    FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
    FDA press release β†—

August 2026

July 2026

  • 31Fri
    FDA approval
    Dr Reddys Labs SA Β· Zimrixby (rituximab-cdxx)
    New biologic licence
    Drugs@FDA β†—
  • 24Fri
    FDA approval
    Outlook Therapeutics, Inc. Β· Lytenava (bevacizumab-vikg)
    New biologic licence
    Drugs@FDA β†—